Literature DB >> 8527721

Amyloidosis, advanced glycation end products and Alzheimer disease.

M A Smith, V M Monnier, L M Sayre, G Perry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8527721     DOI： 10.1097/00001756-199508000-00001

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


× No keyword cloud information.
  6 in total

Review 1.  Role of RAGE in Alzheimer's Disease.

Authors:  Zhiyou Cai; Nannuan Liu; Chuanling Wang; Biyong Qin; Yingjun Zhou; Ming Xiao; Liying Chang; Liang-Jun Yan; Bin Zhao
Journal:  Cell Mol Neurobiol       Date:  2015-07-15       Impact factor: 5.046

2.  Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus.

Authors:  Yan Hong; Chao Shen; Qingqing Yin; Menghan Sun; Yingjuan Ma; Xueping Liu
Journal:  Neurochem Res       Date:  2016-01-06       Impact factor: 3.996

Review 3.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Eugenio Barone
Journal:  Biochim Biophys Acta       Date:  2014-06-17

Review 4.  The contribution of luteinizing hormone to Alzheimer disease pathogenesis.

Authors:  Kate M Webber; George Perry; Mark A Smith; Gemma Casadesus
Journal:  Clin Med Res       Date:  2007-10

Review 5.  RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.

Authors:  Shirley ShiDu Yan; Doris Chen; Shiqian Yan; Lan Guo; Heng Du; John Xi Chen
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

6.  Analysis of protein glycation using fluorescent phenylboronate gel electrophoresis.

Authors:  Marta P Pereira Morais; Dominic Marshall; Stephen E Flower; Christopher J Caunt; Tony D James; Robert J Williams; Nicholas R Waterfield; Jean M H van den Elsen
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.